Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients

J Fungi (Basel). 2021 Jan 22;7(2):76. doi: 10.3390/jof7020076.


Mold-active azole antifungals are commonly prescribed for the prevention of invasive fungal infections in lung transplant recipients. Each agent exhibits a unique pharmacologic profile, an understanding of which is crucial for therapy selection and optimization. This article reviews pharmacologic considerations for three frequently-used azole antifungals in lung transplant recipients: voriconazole, posaconazole, and isavuconazole. Focus is drawn to analysis of drug-interactions, adverse drug reactions, pharmacokinetic considerations, and the role of therapeutic drug monitoring with special emphasis on data from the post-lung transplant population.

PMID:33499209 | DOI:10.3390/jof7020076